Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from BerGenBio ASA ( (BRRGF) ).
Oncoinvent ASA has completed a merger, resulting in the allocation of consideration shares to former shareholders, including primary insiders. This strategic move is expected to strengthen Oncoinvent’s market position as it continues to advance its promising clinical trials for Radspherin®, which have shown encouraging early efficacy data without serious safety concerns.
The most recent analyst rating on (BRRGF) stock is a Buy with a NOK38.00 price target. To see the full list of analyst forecasts on BerGenBio ASA stock, see the BRRGF Stock Forecast page.
More about BerGenBio ASA
Oncoinvent ASA is a clinical-stage biotechnology company focused on developing novel radiopharmaceutical therapies for cancer treatment. Its lead product, Radspherin®, utilizes the alpha-emitting radionuclide radium-224 to target micro-metastases post-surgery, aiming to provide the benefits of modern radiopharmaceuticals without complex biological targeting. The company is conducting clinical trials in the US, UK, and Europe and operates a manufacturing facility in Oslo.
YTD Price Performance: -85.45%
Average Trading Volume: 87,196
Current Market Cap: NOK186.4M
Find detailed analytics on BRRGF stock on TipRanks’ Stock Analysis page.